Illumina Accelerator
Status
INACTIVE
Global HQ
California, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
- Series A
Industries
- Genomics
- Life Sciences
- Health Tech
About
Illumina Accelerator, a subsidiary of Illumina, is at the forefront of biotechnology innovation, specializing in sequencing and array-based solutions for comprehensive genetic analysis. By combining cutting-edge technology with expert mentorship, Illumina Accelerator nurtures early-stage companies aiming to revolutionize life sciences, translational genomics, and molecular diagnostics. Their commitment to empowering groundbreaking research and development enables scientists and entrepreneurs to unlock the full potential of genomic data, driving advancements that can transform healthcare and improve patient outcomes worldwide. With a robust platform that supports innovation, Illumina Accelerator is shaping the future of precision medicine and genomic technologies.
Illumina Accelerator, a subsidiary of Illumina, is at the forefront of biotechnology innovation, specializing in sequencing and array-based solutions for comprehensive genetic analysis. By combining cutting-edge technology with expert mentorship, Illumina Accelerator nurtures early-stage companies aiming to revolutionize life sciences, translational genomics, and molecular diagnostics. Their commitment to empowering groundbreaking research and development enables scientists and entrepreneurs to unlock the full potential of genomic data, driving advancements that can transform healthcare and improve patient outcomes worldwide. With a robust platform that supports innovation, Illumina Accelerator is shaping the future of precision medicine and genomic technologies.
Investment Thesis
Illumina Accelerator supports early stage companies focused on developing transformative technologies in genomics and life sciences, with an emphasis on improving human health.
Manager's Experience
With a background in developing innovative solutions, the fund manager has actively engaged in the biotechnology and life sciences sectors, overseeing numerous investments primarily in North America and Europe. The portfolio reflects a strategic operator-first approach, focusing on early to growth-stage companies while facilitating impactful exits. Having successfully completed over 25 deals, notable achievements include several high-profile acquisitions that underscore a commitment to accelerating breakthroughs in genomic technology. This data-driven investment style emphasizes collaboration with entrepreneurs to foster sustainable growth.